BR0307521A - Inibidores de adesão da célula mediada por alfa l beta2 integrina - Google Patents

Inibidores de adesão da célula mediada por alfa l beta2 integrina

Info

Publication number
BR0307521A
BR0307521A BR0307521-4A BR0307521A BR0307521A BR 0307521 A BR0307521 A BR 0307521A BR 0307521 A BR0307521 A BR 0307521A BR 0307521 A BR0307521 A BR 0307521A
Authority
BR
Brazil
Prior art keywords
alpha
cell adhesion
adhesion inhibitors
mediated cell
beta2 integrin
Prior art date
Application number
BR0307521-4A
Other languages
English (en)
Inventor
Ila Sircar
Marshall Morningstar
Masatoshi Kakushima
Hidefumi Kaji
Takayuki Kawaguchi
Toshiyuki Kume
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of BR0307521A publication Critical patent/BR0307521A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)

Abstract

"INIBIDORES DE ADESãO DA CéLULA MEDIADA POR ALFA~ L~BETA~ 2~ INTEGRINA". A presente invenção refere-se a um composto de fórmula (I): em que R é um átomo de hidrogênio, um grupo hidroxila ou um grupo carbamoíla e n é 1 ou 2 ou um sal farmaceuticamente aceitável do mesmo.
BR0307521-4A 2002-02-07 2003-02-06 Inibidores de adesão da célula mediada por alfa l beta2 integrina BR0307521A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35430902P 2002-02-07 2002-02-07
PCT/US2003/003449 WO2003066636A1 (en) 2002-02-07 2003-02-06 Inhibitors of alpha l beta 2 integrin mediated cell adhesion

Publications (1)

Publication Number Publication Date
BR0307521A true BR0307521A (pt) 2004-12-28

Family

ID=27734354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307521-4A BR0307521A (pt) 2002-02-07 2003-02-06 Inibidores de adesão da célula mediada por alfa l beta2 integrina

Country Status (23)

Country Link
US (1) US7375128B2 (pt)
EP (1) EP1472257B1 (pt)
JP (1) JP2005517016A (pt)
KR (1) KR100625379B1 (pt)
CN (1) CN1301255C (pt)
AR (1) AR040068A1 (pt)
AT (1) ATE411995T1 (pt)
AU (1) AU2003210862B2 (pt)
BR (1) BR0307521A (pt)
CA (1) CA2474748A1 (pt)
CO (1) CO5601028A2 (pt)
DE (1) DE60324250D1 (pt)
EC (1) ECSP045222A (pt)
MX (1) MXPA04007643A (pt)
MY (1) MY137878A (pt)
NO (1) NO20043563L (pt)
NZ (1) NZ534208A (pt)
PE (1) PE20030899A1 (pt)
PL (1) PL372328A1 (pt)
RU (1) RU2315768C2 (pt)
TW (1) TW200303200A (pt)
WO (1) WO2003066636A1 (pt)
ZA (1) ZA200405647B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
KR20080050605A (ko) * 2005-10-06 2008-06-09 노파르티스 아게 Ｌｆａ-ｉ 조정 인자로서의 테트라히드로-피롤리지논화합물
CN101638429B (zh) * 2009-08-28 2012-01-25 南方医科大学 一种特异性识别细胞表面整合素α3β1的小分子肽
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
EP3969066A4 (en) * 2019-05-16 2023-10-04 Dispensing Dynamics International, Inc. PERFUME DISPENSERS AND METHODS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643748A1 (de) 1986-12-20 1988-06-30 Hoechst Ag Bicylische imide, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
CN1249748A (zh) 1997-03-03 2000-04-05 贝林格尔·英格海姆药物公司 用于治疗炎症疾病的小分子
AU7445498A (en) 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
PT1307455E (pt) * 1999-10-20 2005-06-30 Tanabe Seiyaku Co Inibidores de adesao celular mediada por (alfa)l (beta)2

Also Published As

Publication number Publication date
KR20040091625A (ko) 2004-10-28
ZA200405647B (en) 2005-07-15
DE60324250D1 (de) 2008-12-04
RU2004123219A (ru) 2006-02-10
AU2003210862A1 (en) 2003-09-02
KR100625379B1 (ko) 2006-09-20
ECSP045222A (es) 2006-04-19
MY137878A (en) 2009-03-31
PL372328A1 (en) 2005-07-11
RU2315768C2 (ru) 2008-01-27
EP1472257B1 (en) 2008-10-22
TW200303200A (en) 2003-09-01
US20050171174A1 (en) 2005-08-04
CN1301255C (zh) 2007-02-21
AR040068A1 (es) 2005-03-16
EP1472257A1 (en) 2004-11-03
NZ534208A (en) 2005-12-23
MXPA04007643A (es) 2005-06-08
AU2003210862B2 (en) 2006-10-26
NO20043563L (no) 2004-11-01
JP2005517016A (ja) 2005-06-09
ATE411995T1 (de) 2008-11-15
PE20030899A1 (es) 2003-10-25
CO5601028A2 (es) 2006-01-31
CA2474748A1 (en) 2003-08-14
WO2003066636A1 (en) 2003-08-14
US7375128B2 (en) 2008-05-20
CN1628116A (zh) 2005-06-15

Similar Documents

Publication Publication Date Title
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
BR0307575A (pt) Derivados de sulfonila como inibidores de histona desacetilase
BR0016818A (pt) Inibidores não-peptidila de adesão celular dependente de vla-4 úteis no tratamento de doenças inflamatórias, auto-imunes e respiratórias
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
ATE485258T1 (de) Glycyrrhetinsäurederivate und ihre verwendung zur herstellung eines medikaments zur hemmung der 11- beta-hydroxysteroid dehydrogenase
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
BRPI0013667B8 (pt) derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos e seus intermediários na produção deles
BR0005703A (pt) Compostos de sulfamoil-heteroarilpirazole com agentes anti-inflamatórios/analgésicos
MXPA02011632A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
BR0215622A (pt) Inibidores da dpiv com base em glutaminila
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
EP1541559A4 (en) 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE
TR200003333T2 (tr) Ensülin direngenliği ve hiperglisemi tedavisinde yararlı benzotiyofenler
BR0013248A (pt) Inibidores da adesão celular
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BR0307521A (pt) Inibidores de adesão da célula mediada por alfa l beta2 integrina
SE0202429D0 (sv) Novel Compounds
BR0206372A (pt) Processo para sintetizar um composto
WO2002030867A3 (en) Drugs for diabetes
BR0311410A (pt) Composto de piperidina
BR0314844A (pt) Novo composto
WO2002092072A3 (en) Drugs for the treatment of the alzheimer disease
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MITSUBISHI TANABE PHARMA CORPORATION (JP)

Free format text: ALTERADO DE: TANABE SEIYAKU CO ., LTD.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.